SecBot SecBot

CYTK

CYTOKINETICS INC
Nasdaq· Pharmaceutical Preparations· CIK 0001061983 Biotech & Drug Discovery
$53.17 −2.96 (−5.27%)
Nov 16 4:00 PM ET · prev $56.13
Market cap
$7.8B
Mid cap
Consensus
Buy
89% Buy or better · 28 analysts
Median target
$107.00
+101% · range $78.00–146.00
1 year
−20.6%
from $66.95 · Nov 17
30 days
−15.1%
from $62.65
52-week range
$53.17–87.26
at the low
Avg volume 20D
1.98M
Nov 5 spike 6.77M
Short interest
17.93M
≈12.9% of shares · −3.8%
Days to cover
14.2
at average volume
Insider net
−$14.8M
0 buyers · 5 sellers · since Jul 15
New fund stakes
4
Q2 2026 13F · 2 exits
Filing reports
37
analyzed by SecBot
SecBot read MIXED 20 reports · 90 days
Balance 3 bearish · 3 bullish · 14 neutral oldest → newest, height = score
Avg score ·High conf. 14/20

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

  • May 5 ▲ Cytokinetics announced positive topline results from the ACACIA-HCM…
  • Jun 30 ▲ 4 funds open new positions (13F)
  • Jul 21 to Jul 30 ▼ 3 days of insider sells: $2.0M by 3 insiders, avg $80.28
  • Aug 10 ▼ 1 insider sell $575.7K at $76.76
  • Aug 18 ▼ 1 insider sell $265.4K at $75.82
  • Aug 31 to Sep 28 ▼ 8 days of insider sells: $10.1M by 5 insiders, avg $69.71
  • Sep 29 ▲ Gilbert Cisneros bought $1,001 - $15,000, last disclosed Oct 13
  • Oct 6 to Oct 12 ▼ 2 days of insider sells: $686.4K by 2 insiders, avg $62.40
  • Oct 16 William Blair initiates
  • Oct 20 ▼ 1 insider sell $224.0K at $64.01
  • Nov 2 to Nov 9 ▼ 3 days of insider sells: $965.0K by 3 insiders, avg $60.31
  • Nov 9 FDA: Cytokinetics Announces Additional Data Related to Aficamte…

Signal stack

Where each data set points today.

  • InsidersBEARISH

    5 insiders sold $14.8M.

  • InstitutionsBULLISH

    Q2 2026: 60 added (4 new), 20 trimmed or exited. Largest new: Holocene Advisors $97.5M, Hood River Capital Management $40.0M.

  • AnalystsBULLISH

    25 of 28 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −3.8% to 17.93M shares. 14.2 days to cover, ≈12.9% of shares.

  • TrendDOWNTREND

    17% below its 50-day average. New closing low $53.17 on Nov 16.

Who's buying

13F· Q2 2026
4
new positions
2
exits
$175.9M
in new stakes
FundMoveSharesValue
FMR LLCTRIM5,031,782$428.7M
Avoro Capital Advisors LLCADD4,999,999$425.9M
BANK OF AMERICA CORP /DE/ADD4,635,709$394.9M
Polar Capital Holdings PlcADD2,253,649$192.0M
Capital Research Global InvestorsDOUBLED1,686,625$143.7M
JPMORGAN CHASE & COADD1,588,895$139.2M
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLCADD1,603,442$136.6M
Point72 Asset Management, L.P.DOUBLED1,587,712$135.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

28 analysts
Buy 89% rate it Buy or better
Strong Buy7Buy18Hold3Sell0Strong Sell0
12-month targets · 19 analysts

Price is below the lowest target. Median implies +101%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 5, 2026Citigroup
MAINTAIN
MAINTAINBuy
Nov 5, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Oct 19, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Oct 16, 2026William Blair
INITIATE
INITIATEOutperform
Oct 8, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Aug 31, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Washington

Corporate Lobbying

8 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$0
bought · 0 insiders
$14.8M
sold · 5 insiders
DateInsiderTypeValue
Nov 9, 2026
PARSHALL B LYNNE
Director
Nov 9, 2026
SELL$132.4K
Nov 9, 2026
PARSHALL B LYNNE
Director
Nov 9, 2026
SELL$141.2K
Nov 3, 2026
Malik Fady Ibraham
EVP Research & Development
Nov 3, 2026
EXERCISE$27.3K
Nov 3, 2026
Malik Fady Ibraham
EVP Research & Development
Nov 3, 2026
SELL$220.3K
Nov 2, 2026
Blum Robert I
President & CEO
Nov 2, 2026
SELL$471.1K
Nov 2, 2026
Blum Robert I
President & CEO
Nov 2, 2026
EXERCISE$79.5K
Oct 20, 2026
Malik Fady Ibraham
EVP Research & Development
Oct 20, 2026
EXERCISE$27.3K
Oct 20, 2026
Malik Fady Ibraham
EVP Research & Development
Oct 20, 2026
SELL$224.0K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q-$1.28-$1.55–-$0.73+3.9%$75.3M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Congressional trades
CYTK trades disclosed by members of Congress, with disclosure delay.
1 members · 2 buys / 0 sells
DateMemberType AmountDisclosed
Sep 29, 2026 Gilbert CisnerosDHouse CYTOKINETICS INC BUY $1K–$15K Oct 12, 2026 +13d
Jun 30, 2026 Gilbert CisnerosDHouse CYTOKINETICS INC BUY $1K–$15K Jul 2, 2026 +2d

Short side

FINRA· Oct 30, 2026
17,929,635
shares short
-3.8%
vs prior settlement
14.2
days to cover
≈12.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 Other
🔒 Fresh data, subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 12, 2026 SEC
Three Cytokinetics insiders, including the CEO and EVP of R&D, sold a total of $824K in open-market sales over a week…
CLUSTER · Impact 3/10
Nov 10, 2026 SEC
State Street Corp disclosed a 5.1% passive stake in Cytokinetics via Schedule 13G, holding 7,143,229 shares as of…
SC 13G · Impact 3/10
Nov 9, 2026 Press
Cytokinetics presented new aficamten data at HCMS/AHA 2026, including positive cardiac remodeling and patient-reported…
Impact 4/10
Nov 9, 2026 Insider
PARSHALL B LYNNE sold 2,445 shares
Director @ $54.17 ($132.4K)
Nov 9, 2026 Insider
PARSHALL B LYNNE sold 2,555 shares
Director @ $55.26 ($141.2K)
Nov 3, 2026 Insider
Malik Fady Ibraham acquired via exercise 3,500 shares
EVP Research & Development @ $7.80 ($27.3K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent

SecBot reports

37 filings · 9 press releases · 2 bullish · 6 bearish · 3 mixed · 26 neutral
All CYTK filing & press-release reports (46)